QIAGEN Aktie 35465310 / NL0012169213
45.59
USD
0.15
USD
0.32%
10:32:11
NDN
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | Ausblick | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 98.81 |
| BlackRock Fund Advisors | 15.12 |
| Massachusetts Financial Services Co. | 9.31 |
| Schroder Investment Management Ltd. (13F Subfiler) | 2.92 |
| Government Pension Fund - Global (The) | 2.78 |
| PSquared Asset Management AG | 2.72 |
| Vanguard Group, Inc. (Subfiler) | 2.66 |
| Norges Bank (13F) | 2.52 |
| UBS Asset Management (Americas), Inc. | 2.05 |
| Pendal Group Ltd. | 1.89 |
| MFS International Growth Fund | 1.69 |
| MFS Research International Fund | 1.65 |
| DZ BANK AG Deutsche Zentral-Genossenschaftsbank | 1.53 |
| Vanguard Total International Stock Index Fund | 1.28 |
| DekaBank Deutsche Girozentrale | 1.27 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 4'952 | 5'096 | 5'610 | 6'028 | 6'178 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.30 | 0.30 | 0.33 | 0.37 | 0.35 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 2'155 | 1'570 | 1'667 | 2'110 | 2'394 |
| Summe Anlagevermögen | 4'809 | 4'301 | 4'830 | 5'137 | 5'422 |
| Summe Aktiva | 5'748 | 5'236 | 5'913 | 6'147 | 6'288 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 2'174 | 1'765 | 2'032 | 2'040 | 1'955 |
| Summe Fremdkapital | 3'113 | 2'699 | 3'115 | 3'050 | 2'821 |
| Summe Eigenkapital | 2'635 | 2'537 | 2'798 | 3'097 | 3'467 |
| Summe Passiva | 5'748 | 5'236 | 5'913 | 6'147 | 6'288 |
Adresse
| Hulsterweg 82, 5912 PL Venlo | |
| Telefon | +31 (77) 355-66-00 |
| Fax | +31 (77) 355-66-58 |
| URL | http://www.qiagen.com |
Management
|
Antonio Santos
Senior Vice President & Head-Global Operations |
|
Elaine R. Mardis
Independent Member-Supervisory Board |
|
Elizabeth E. Tallett
Member-Supervisory Board |
|
Eva Pisa
Member-Supervisory Board |
|
Jean-Pascal Viola
Head-Corporate Business Development |
|
John Gilardi
Vice President & Head-Investor Relations |
|
Jonathan G. Sheldon
Senior VP-Digital Insights Business Area |
|
Lawrence A. Rosen
Chairman-Supervisory Board |
|
Lezette Young
Manager-Compliance & Legal |
|
Metin Colpan
Independent Member-Supervisory Board |
|
Nedal Safwat
VP & Head-Molecular Diagnostics North America |
|
Philipp von Hugo
VP, Head-Global Legal Affairs & Compliance |
|
Roland Sackers
Chief Financial Officer & Managing Director |
|
Ross L. Levine
Independent Member-Supervisory Board |
|
Stephany Foster
Chief Human Resources Officer & Senior VP |
|
Stephen H. Rusckowski
Member-Supervisory Board |
|
Thierry Bernard
Chief Executive Officer & Managing Director |
|
Thomas Ebeling
Member-Supervisory Board |
|
Thomas Neidert
Vice President-Global Treasury |
|
Thomas Schweins
Senior Vice President-Life Science Business Area |
|
Thomas Theuringer
Senior Director & Head-External Communications |
|
Toralf Haag
Member-Supervisory Board |
|
Ulrich Schriek
Senior Advisor |